- Home
- ADMA vs TGTX Comparison
ADMA vs TGTX Comparison
Compare ADMA & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADMA
- TGTX
- Stock Information
- Founded
- ADMA 2004
- TGTX 1993
- Country
- ADMA United States
- TGTX United States
- Employees
- ADMA N/A
- TGTX N/A
- Industry
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ADMA Health Care
- TGTX Health Care
- Exchange
- ADMA Nasdaq
- TGTX Nasdaq
- Market Cap
- ADMA 5.3B
- TGTX 5.4B
- IPO Year
- ADMA N/A
- TGTX 1995
- Fundamental
- Price
- ADMA $21.18
- TGTX $35.07
- Analyst Decision
- ADMA Strong Buy
- TGTX Strong Buy
- Analyst Count
- ADMA 4
- TGTX 6
- Target Price
- ADMA $21.25
- TGTX $37.67
- AVG Volume (30 Days)
- ADMA 3.9M
- TGTX 4.5M
- Earning Date
- ADMA 11-07-2024
- TGTX 11-04-2024
- Dividend Yield
- ADMA N/A
- TGTX N/A
- EPS Growth
- ADMA N/A
- TGTX N/A
- EPS
- ADMA 0.28
- TGTX N/A
- Revenue
- ADMA $382,809,000.00
- TGTX $264,790,000.00
- Revenue This Year
- ADMA $60.41
- TGTX $43.74
- Revenue Next Year
- ADMA $13.09
- TGTX $64.30
- P/E Ratio
- ADMA $75.56
- TGTX N/A
- Revenue Growth
- ADMA 63.39
- TGTX 39.53
- 52 Week Low
- ADMA $3.60
- TGTX $12.30
- 52 Week High
- ADMA $23.64
- TGTX $36.50
- Technical
- Relative Strength Index (RSI)
- ADMA 59.66
- TGTX 69.73
- Support Level
- ADMA $18.90
- TGTX $28.59
- Resistance Level
- ADMA $21.70
- TGTX $36.40
- Average True Range (ATR)
- ADMA 1.13
- TGTX 2.64
- MACD
- ADMA 0.08
- TGTX 0.45
- Stochastic Oscillator
- ADMA 51.48
- TGTX 88.91
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.